The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Being overweight or obese (OW/OB) has been associated with an increased risk of developing several different malignancies. More specifically, preexisting obesity has been associated with an increased risk of childhood B-cell acute lymphoblastic leukemia (B-ALL). Notably, as many as 40% of adolescents and young adult patients begin B-ALL induction therapy as OW/OB. Patients in this setting are known to have increased chemoresistance and measurable residual disease (MRD) positivity, which can lead to significant clinical ramifications and poor prognosis.
Recently, new scientific research has suggested that the negative effects of OW/OB physiology could be corrected with appropriate interventions. Therefore, Etan Orgel and colleagues hypothesized that inducing a caloric and nutrient restriction through diet and exercise could reduce gains in fat mass (FM), reverse overweight physiology, and improve chemosensitivity by decreasing postinduction MRD. The authors further hypothesized that lean patients could also benefit from this intervention.1
Table 1. Summary of IDEAL intervention*
*Adapted from Orgel, et al.1 |
|
Education topic |
Approach |
---|---|
Diet and exercise benefits during induction |
Integrated into physician conference and assessment of diet by a dietician and activity by a physiotherapist |
Food selection and portion control |
Individualized menus, Traffic Light, My Plate |
Safe exercise during chemotherapy |
Instruction, demonstration by physiotherapist |
Diet intervention |
Daily intake goal |
Caloric deficit |
≥10% |
Protein |
≥20% of total calories |
Fat |
<25% of total calories |
Carbohydrate |
<55% of total calories |
Low glycemic load |
<100/2,000 kcal |
Progression |
Caloric goal ±5% weekly |
Exercise intervention |
Goal |
Caloric expenditure |
≥10% |
Frequency |
Daily |
Intensity |
Moderate exertion |
Time |
15- to 30-min sessions (200 min/week) |
Type |
Aerobic exercise and resistance training |
Location |
Home-based |
Progression |
As tolerated |
a higher BMI and FM at baseline.
Table 2. Patient characteristics*
SD, standard deviation. |
|||
Characteristic |
IDEAL trial |
Historical control |
p value† |
---|---|---|---|
Age, years |
|
|
|
Mean ± SD |
15.0 ± 3.0 |
14.7 ± 2.5 |
0.72 |
10.0–14.9, n (%) |
19 (48) |
46 (58) |
0.34 |
≥15, n (%) |
21 (52) |
34 (42) |
|
Sex, n (%) |
|
|
|
Female |
16 (40) |
37 (46) |
0.56 |
Male |
24 (60) |
43 (54) |
|
Ethnicity, n (%) |
|
|
|
Not Hispanic |
8 (20) |
14 (18) |
0.002 |
Hispanic, |
26 (65) |
66 (83) |
|
Not reported |
6 (15) |
0 (0) |
|
White blood cell count, ×103/μL |
|
|
|
Mean ± SD |
56 ± 117 |
50 ± 93 |
0.54 |
<50, n (%) |
31 (70) |
57 (71) |
0.52 |
≥50, n (%) |
9 (23) |
23 (29) |
|
Cytogenetics‡, n (%) |
|
|
|
Neutral |
18 (45) |
61 (76) |
<0.001 |
Favorable |
3 (7) |
10 (13) |
|
Adverse |
19 (48) |
8 (10) |
|
Unknown |
0 (0) |
1 (1) |
|
BMI category, n (%) |
|
|
|
Lean |
14 (35) |
45 (56) |
0.09 |
Overweight |
6 (15) |
9 (11) |
|
Obese |
20 (50) |
26 (33) |
|
BMI percentile, % |
79.5 ± 27.3 |
67.2 ± 32.8 |
0.03 |
Body composition§ |
|
|
|
Fat mass, kg |
25.2 ± 14.1 |
18.4 ± 11.3 |
0.04 |
% fat |
32.7 ± 9.6 |
27.8 ± 9.0 |
0.02 |
Lean mass, kg |
45.3 ± 14.7 |
39.5 ± 12.5 |
0.11 |
% lean |
64.4 ± 9.2 |
68.9 ± 8.5 |
0.02 |
Figure 1. Prevalence of EOI MRD positivity stratified by BMI category1
BMI, body mass index; EOI, end of induction; MRD, measurable residual disease; OW/OB, overweight/obese.
*Adapted from Orgel, et al.1
This is the first prospective trial in a hematologic malignancy to demonstrate the feasibility and potential benefit of caloric restriction via diet and exercise on chemotherapy efficacy and disease response. The IDEAL intervention did not significantly reduce fat gain in the overall cohort compared with the historical control, however stratified analysis demonstrated benefit in patients who were OW and OB. After accounting for prognostic factors, the IDEAL intervention reduced the risk of EOI MRD in all patients. The insulin-glucose pathway and adiponectin were identified as potential mediators of chemoresistance and IDEAL efficacy. Limitations include poor adherence to the exercise component of the intervention, as well as the incorporation of a nonrandomized historical control.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content